Omeros Corp (OMER) Gets a Hold Rating from Wedbush

By Jason Carr

Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros Corp (OMERResearch Report) today and set a price target of $18. The company’s shares closed last Monday at $19.25.

According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.9% and a 30.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros Corp with a $28.33 average price target.

See today’s analyst top recommended stocks >>

Based on Omeros Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.45 million. In comparison, last year the company had a GAAP net loss of $33.7 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.